Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CCR2 | P41597 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747206 | 0.87 | CXCR4 (0.65) | — | |
| SCHEMBL12156613 | 0.86 | SIGMAR1 (0.58) | ALDH1A1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL6620535 | 0.86 | SLC6A4 (0.51) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL9537230 | 0.86 | BCHE (0.63) | — | |
| SCHEMBL5743274 | 0.85 | SIGMAR1 (0.59) | ALDH1A1SIGMAR1MEN1KMT2A | |
| SCHEMBL23086760 | 0.85 | DRD2 (0.48) | DRD2DRD4 | |
| SCHEMBL8409945 | 0.82 | GAA (0.49) | — | |
| SCHEMBL2073212 | 0.81 | DRD2 (0.60) | ALDH1A1DRD2DRD4SIGMAR1MEN1 | |
| SCHEMBL3593316 | 0.81 | CCR2 (0.67) | ALDH1A1SIGMAR1CCR2 | |
| SCHEMBL14049579 | 0.80 | SIGMAR1 (0.52) | ALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6444819-B1 | NEUROLEPTIC AGENTS;D4 RECEPTOR ANTAGONIST;SIDE EFFECT REDUCTION;SCHIZOPHRENIA;DRUG ABUSE, DRUG DEPENDENCE; ANXIOLYTICS; ANTIDEPRESSANTS;COGNITION ACTIVATORS. | NEUROGEN CORPORATION | 2002-09-03 | — | — | US | disclosed |
| US-20020045626-A1 | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-04-18 | — | — | US | disclosed |
| US-6316470-B1 | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2001-11-13 | — | — | US | disclosed |
| EP-1068193-A1 | BENZYLPIPERAZINYL- AND BENZYLPIPERIDINYL ETHANONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE D 4? RECEPTOR ANTAGONISTS | NEUROGEN CORPORATION (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6084098-A | HIGH AFFINITY AND SELECTIVITY IN BINDING TO THE D4 RECEPTOR SUBTYPE; NEUROLEPTIC, DOPAMINERGIC AGENTS; SCHIZOPHRENIA, MANIA, COMPULSIVE BEHAVIOR, SUBSTANCE ABUSE; ANTIDEPRESSANTS; ANXIOLYTIC AGENTS; PARKINSONISM; TARDIVE DYSKINESIAS; CNS | NEUROGEN CORPORATION (US) | 2000-07-04 | — | — | US | disclosed |
| WO-1999043670-A1 | BENZYLPIPERAZINYL- AND BENZYLPIPERIDINYL ETHANONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE D4 RECEPTOR ANTAGONISTS | NEUROGEN CORPORATION (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045626-A1 | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands | DRD2, DRD3, OPRD1 | ALDH1A1 1102/4885DRD2 1/4885DRD4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.